Skip Content
You are currently on the new version of our website. Access the old version .
AntibioticsAntibiotics
  • This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
  • Article
  • Open Access

4 February 2026

Etiopathogenesis and Antibacterial Therapy Approach in Patients with Acute Obstructive Pyelonephritis—A Retrospective Study

,
,
,
,
,
,
and
1
Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
2
Department of Urology, Colentina Clinical Hospital, 020125 Bucharest, Romania
3
Department of General Surgery, Colentina Clinical Hospital, 020125 Bucharest, Romania
4
Department of Urology, Fundeni Clinical Institute, 022328 Bucharest, Romania
This article belongs to the Special Issue Urinary Tract Infections and Antibiotic Intervention, 2nd Edition

Abstract

Objectives: Acute obstructive pyelonephritis (AOP) is a urological emergency that combines bacterial infection with upper urinary tract obstruction. This retrospective study focuses on the microbial etiology and causes of obstruction, clinical manifestations, antibacterial therapy, drainage type, and outcomes in patients diagnosed with AOP at a tertiary urology center between 1 January 2020 and 30 December 2024. Methods: One hundred patients with a mean age of 61.30 years were included in this retrospective study, which examines demographic data, comorbidities, clinical features, pathogens involved, antimicrobial regimens, and hospital outcomes. Results: Urolithiasis was the most frequent cause of obstruction (62%), followed by ureteral stenosis (14%) and tumors (11%). AOPs were mainly produced by Escherichia coli (58%), followed by Klebsiella spp. (21%); 18% of all identified bacteria were ESBL-producing Gram-negative bacilli, and 29% were MDR bacteria. The most used IV antibiotics were fluoroquinolones (52%), followed by cephalosporins (19%) and carbapenems (18%). Carbapenems were administered to all patients with AOP caused by ESBL-producing pathogens and to 62% of those with MDR bacteria. The duration of antibiotic therapy was individualized based on clinical response. Switch to oral administration was made after 4.3 ± 1.5 days, and the antibiotic treatment lasted 10.8 ± 3.2 days. Conclusions: The results of the present study support integrating evidence-based guidelines with regional patterns of bacterial susceptibility to optimize therapeutic approaches and reduce severe outcomes in patients with AOP, most of whom have multiple comorbidities.

Article Metrics

Citations

Article Access Statistics

Article metric data becomes available approximately 24 hours after publication online.